Tuesday, February 18, 2014 10:13:53 PM
Oddly enough, most bio's and stem's at this stage are considered to be teetering on bankruptcy. All of them are high risk plays.
The highest % jump for a stock in one day that I’ve seen was @@@@* when their test for cervical cancer was approved. It went from .05 at the open to close at 1.29 which was a 2,480 percent gain in one day. I was watching it after a volume alert went off. The ticker ended with a Q which meant it was in bankruptcy. I thought for sure it was a pump and dump. It moved too fast to even look at the news. My order was set at .50 and I canceled it for fear it was coming right back down. Instead, it kept going until the close of 1.29.
I watched it for months in fascination thinking it was running out of steam and never got in. It was at a high of $34 on 3.8.10 only six months later. $34 from .05 was a 67,000 percent gain in six months.
The right news moves a stock no matter the exchange or financial condition. It would have been a really bad one to be short in.
That was the most horrible play to watch get away. Lol
*Anyone wanting to know the ticker can pm me.
In Reply to 'Rawnoc'
What is the present value of a development stage biopharma start-up that eventually goes completely bust like NNVC will?
The highest % jump for a stock in one day that I’ve seen was @@@@* when their test for cervical cancer was approved. It went from .05 at the open to close at 1.29 which was a 2,480 percent gain in one day. I was watching it after a volume alert went off. The ticker ended with a Q which meant it was in bankruptcy. I thought for sure it was a pump and dump. It moved too fast to even look at the news. My order was set at .50 and I canceled it for fear it was coming right back down. Instead, it kept going until the close of 1.29.
I watched it for months in fascination thinking it was running out of steam and never got in. It was at a high of $34 on 3.8.10 only six months later. $34 from .05 was a 67,000 percent gain in six months.
The right news moves a stock no matter the exchange or financial condition. It would have been a really bad one to be short in.
That was the most horrible play to watch get away. Lol
*Anyone wanting to know the ticker can pm me.
In Reply to 'Rawnoc'
What is the present value of a development stage biopharma start-up that eventually goes completely bust like NNVC will?
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
